Last updated on December 2007

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel Adriamycin Cyclophosphamide) Chemotherapy


Brief description of study

This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients treated with TAC chemotherapy. Maxy-G34 will be given as a single injection during each cycle of chemotherapy, for a planned total of six chemotherapy cycles.

Clinical Study Identifier: NCT00501332

Contact Investigators or Research Sites near you

Start Over

Doris Apt

St. Petersburg, Russian Federation
  Connect »